Stephen Hahn, FDA Commissioner recently acknowledged the need to ramp up testing. His tone was cautious on Sunday and the message was clear-  Having an inaccurate test is worse than no test at all.

 Hahn said during an appearance on ABC’s show, “This Week,” “further ramping up testing, both diagnostic as well as the antibody tests, will really be necessary as we move beyond May into the summer months and then into the fall.” The doctor also added that the United States has done more than 2 million tests, but stated: “We need to do more. No question about that.”

The diagnostic testing in the U.S. has mostly focused on those with the most severe symptoms and has been administered to less than 1 percent of the population. Hahn pointed towards pressure on the supply chain as the main factor for disparities in access to testing across the country — and why nations like Germany and South Korea are able to test at much higher rates.

Still, the commissioner warned that as pressures mount on the Trump administration to increase testing capabilities: The science behind the tests has to be “the right science.”

“There’s going to be plenty of time to look back on this,” Hahn said during his appearance on NBC’s “Meet the Press.” “It’s really important to remember that these tests have to be valid and accurate and reliable.”

“I am concerned that some of the antibody tests that are in the market that haven’t gone through the FDA scientific review may not be as accurate as we’d like them to be,” Hahn said on NBC. “No test is 100 percent perfect. But what we don’t want are wildly inaccurate tests. Because, as I said before, that’s going to be much worse.”

Hahn hesitated to say whether President Trump’s May 1 target to lift social distancing guidelines is achievable or realistic. Health experts have called it an aggressive deadline, stating that robust testing and contact tracing capabilities should be prioritized to avoid future outbreaks at this current scale.

He said during his interview on ABC: “It is a target. And obviously, we’re hopeful about that target. But I think it’s just too early to be able to tell that.”